Search - tctmd.com

Displaying 421 - 440 of 491

Sort: Relevancy | Date

Presentation TCT 2013

Stroke, Bleeding and Risk Scores in Atrial Fibrillation (with and without Anticoagulation)

Presenter: Stefan Bertog

October 27, 2013

Presentation TCT 2013

Multicenter Experience with the ACP for Stroke Prevention in Atrial Fibrillation

Presenter: Apostolos Tzikas

October 27, 2013

Presentation TCT 2013

Management of Patients with Atrial Fibrillation and Stents

Presenter: Neal Kleiman

October 27, 2013

Presentation TCT 2013

LAA Closure in Valvular Atrial Fibrillation (and TAVR Patients): Rationale and Results

Presenter: Samir Kapadia

October 27, 2013

Presentation Scripps 2013

Left Atrial Appendage Closure for Atrial Fibrillation: Current Status

Presenter: Matthew J. Price

October 03, 2013

Presentation

High Sensitivity Troponin T and Risk Stratification in Patients with A-fib on Apixaban or Warfarin

Presenter: Ziad Hijazi

October 02, 2013

Presentation ESC 2013

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Presenter: Alvaro Avezum

September 03, 2013

Presentation

Atrial Fibrillation in MI Patients: Impact on Health Care Utilization

Presenter: A.M. Chamberlain

August 27, 2013

Presentation

Higher Persistence in Newly Diagnosed Nonvalvular A-fib Patients Treated with Dabigatran vs. Warfarin

Presenter: M. Zalesak

August 12, 2013

Presentation

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

Presenter: David Garcia

August 05, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

Presentation

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

Presenter: B. A. Steinberg

July 24, 2013

Presentation

RE-LY: Dabigatran vs. Warfarin and Hemorrhagic Stroke in Asians and Non-Asians with A-fib

Presenter: M. Hori

June 21, 2013

Presentation

Risks and Benefits of Anticoagulation in Atrial Fibrillation

Presenter: MW Cullen

June 20, 2013

Presentation TVT 2013

EP Perspective: Where Will A-fib Ablation Take Us in the Next Five Years?

Presenter: Darryl Wells

June 15, 2013

Presentation TVT 2013

Defining Nonvalvular A-fib: Not So Simple

Presenter: Michael Ezekowitz

June 15, 2013

Presentation TVT 2013

"New" Anticoagulation Options for A-fib: Beyond Warfarin

Presenter: Michael Ezekowitz

June 15, 2013

Presentation TVT 2013

Predictors of TAVR: Associated Strokes: New Onset Atrial Fibrillation, Postdilatation, and Others

Presenter: Josep Rodes-Cabau

June 12, 2013

Presentation

Oral Anticoagulation (OAC) and Antiplatelets inA-fib Patients After MI and PCI

Presenter: M. Lamberts

June 12, 2013

Presentation

Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-fibfib

Presenter: Sean van Diepen

June 10, 2013

Advertisement

Stroke, Bleeding and Risk Scores in Atrial Fibrillation (with and without Anticoagulation)

Multicenter Experience with the ACP for Stroke Prevention in Atrial Fibrillation

Management of Patients with Atrial Fibrillation and Stents

LAA Closure in Valvular Atrial Fibrillation (and TAVR Patients): Rationale and Results

Left Atrial Appendage Closure for Atrial Fibrillation: Current Status

High Sensitivity Troponin T and Risk Stratification in Patients with A-fib on Apixaban or Warfarin

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Atrial Fibrillation in MI Patients: Impact on Health Care Utilization

Higher Persistence in Newly Diagnosed Nonvalvular A-fib Patients Treated with Dabigatran vs. Warfarin

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

RE-LY: Dabigatran vs. Warfarin and Hemorrhagic Stroke in Asians and Non-Asians with A-fib

Risks and Benefits of Anticoagulation in Atrial Fibrillation

EP Perspective: Where Will A-fib Ablation Take Us in the Next Five Years?

Defining Nonvalvular A-fib: Not So Simple

"New" Anticoagulation Options for A-fib: Beyond Warfarin

Predictors of TAVR: Associated Strokes: New Onset Atrial Fibrillation, Postdilatation, and Others

Oral Anticoagulation (OAC) and Antiplatelets inA-fib Patients After MI and PCI

Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-fibfib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content